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Editorial on the Research Topic
Hot Topics of Debate on Turner Syndrome: Growth, Puberty, Cardiovascular Risks, Fertility
and Psychosocial Development
Turner syndrome (TS) is the most common female sex chromosome disorder with an incidence
of 1 in 2,000 to 1 in 2,500 live female births (1). Individuals may be diagnosed at different
stages of life beginning from in utero till adulthood, abnormal maternal screening, or fetal
abnormalities, in infancy through the presence of lymphedema, in childhood as a result of growth
failure, in adolescence as a result of short stature with pubertal delay, and in adulthood as a
result of premature ovarian failure (2). The key to the care of this population includes proactive
screening for co-existing medical conditions, including imaging for cardiac and renal anomalies,
and monitoring for obesity and hypertension, developmental/psychoeducational abnormalities,
hearing loss, autoimmune diseases, and short stature. Ovarian dysfunction and infertility should
be anticipated (2).
The purpose of this Research Topic is to gather together research and review papers, which may
serve to highlight the diverse challenges in the care of females with TS with the expectation that
this will allowmore critical appraisal of existing studies, identify critical research gaps, and pave the
path for future studies.
In terms of addressing issues regarding growth and puberty in females with TS, Gawlik
et al. document successful induction and progression of puberty by transdermal estrogen in
girls with TS at a mean age of 15.1 year over a mean follow-up period of 2.4 year. They
also report adequate increase in uterine size without compromising stature, irrespective of
the karyotype status. Therefore, the fixed-dose transdermal estrogen regimen suggested by
the authors seems to be effective in females with delayed diagnosis of TS. Regarding the
growth and pubertal timing in females with TS, Woelfle et al. present a comprehensive
report based on KIGS R© (Pfizer International Growth Database including 7,219 females with
TS between 1987 and 2012), and they demonstrate evidence of positive secular trends on
age at onset of puberty and on final height akin to that reported on the normal population.
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These finding may be indicative of earlier diagnosis and thus,
of earlier start of GH and estrogen treatments than in the past.
Because KIGS R© data exclusively include GH-treated females
with TS, whether these trends also apply to growth hormone
(GH)-naïve counterparts is currently unknown. However, the
doubling in prevalence in spontaneous puberty does suggest that
environment-related trends may also apply to females with TS.
In addition to induction of puberty, the bone-health
related advantages of estrogen replacement in TS have
been longitudinally evaluated by Li et al. using a regional
estrogen replacement protocol in China, and the authors
report the positive impact of estrogen on bone mineral
density and muscle strength despite a relatively short term
follow-up period.
It is well-established that females with TS are at increased
risk of excess adiposity and its related complications. The
tempo of the derangement in metabolic health profile and
the associated key factors have not been adequately studied.
To this end, Lebenthal et al. document abnormal metabolic
profiles in young prepubertal girls with TS, which confirms
the presence of risk factors inherent to TS itself. The time-
related increase in metabolic derangements with an increase
in prevalence of overweight/obesity status also confirm that
non-TS related factors as in the general population are also
operative in TS. While the more prominent clustering of
metabolic anomalies in females with 45,XO karyotype may
suggest closer follow-up and earlier intervention in this group,
factors associated with a more dismal metabolic outcome
in 45,XO females await further studies. In a theme parallel
with this latter article, Sun et al. review derangements in
pancreatic β- cell function and their reflections on glucose
metabolism in TS. The β- cell failure in TS may be due to
Xp hapotype gene deficiency and to overexpression of some
genes of Xq; this is also an area that also awaits further
studies. Although females with TS are well-established to
have increased autoimmunity, its association with dysglycemia
is currently unestablished. In their review, Sun et al. also
indicate that the theoretical adverse effect of GH therapy on
glycemic regulation in this non-GH deficient population has
not been proven, possibly owing to increase in lean mass with
GH treatment.
In a preliminary report on autoimmunity in TS, Gawlik
et al. find no significant difference between females with TS
and healthy controls regarding regulatory T cell percents,
but in a subgroup analysis between anti- thyroid peroxidase
antibody positive and negative females with TS, a trend toward
iXq karyotype with reduced percents of helper T cells was
observed. These findings call for further studies to reach hard
end-point conclusions on the mechanisms of autoimmunity
in TS.
Thoracic aortic disease, be it congenital or acquired, is a
major determinant of morbidity and mortality in TS [reviewed
in Mortensen et al. (3)]. Cardiovascular risk assessment in TS,
particularly for aortic dissection, unfortunately has remained
inadequate, which is due to a limited understanding of the
pathophysiology of thoracic aortic disease in TS. Cardiovascular
magnetic resonance (CVMR) is the gold standard for non-
invasive assessment of thoracic aortic disease. Obara-Moszynska
et al. confirm the superiority of CVMR over echocardiography
in identifying anomalies such as dilatation of the aorta,
pericardial fluid, and functional impairment of ventricles in a
young females with TS. Aortic dissection has been reported
as early as 4 year in TS (4). However, the availability
of CVMR is limited in many developing countries, and it
requires general anesthesia in patients under 6 years of age.
These shortcomings of CVMR indicate the need to find
potential markers to diagnose aortic pathology in TS. To
this end, Mainkurve and O’Gorman reviewed the potential
role of natriuretic peptides and osteoprogerin for aortic
pathology in TS. While some associations of these markers
have been found with aortic disease, their predictive value
remains to be determined.
While the endocrine- related issues in TS are addressed in
many studies, studies evaluating psychosocial problems in TS
are scant [reviewed in Culen et al. (5)]. Referring to a former
study of theirs (6) and the current study, Anaki et al. document
that dysfunction in social tasks in TS is most likely due to
spatial-visual factors, and that the capacity of females with TS to
understand the emotional and cognitive status of others is similar
to healthy controls.
Rovet and Van Vliet examine a subgroup of females
with TS from the Canadian GH trial regarding potential
psychosocial benefits of of GH treatment. Studies have shown
that short children have been affected by juvenilization, teasing,
bullying, victimization, loss of independence/ overprotection,
and exclusion [reviewed in Lipman and McCurry (7)]. However,
this conclusion has not been strongly confirmed by Rovet and
Van Vliet, who document modest effect of GH treatment on
psychosocial functioning in females with TS. In this study,
Rovet and Van Vliet included a respectable number of patients
with a relatively lower rate of follow-up data loss compared
to other studies (8). Therefore, the authors conclude that it is
important not to overemphasize the benefits of GH treatment on
heightism since final height in many GH treated females with TS
remains suboptimal.
In conclusion, we hope that this Research Topic will serve as
a point of reference and source of inspiration for researchers and
clinicians interested in addressing controversial issues related to
the care of females with TS.
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